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The first chapter in this manuscript serves as an overview of the background, 
significance, and theological framework of this study, comparison of papillary renal cell 
carcinoma type 1 and type 2: a secondary analysis. The body of this work focuses on the topics 
of the current knowledge, genetic variations and syndromes, demographics, increased risk 
factors, and pathways associated with type 1 and type 2 papillary renal cell carcinoma. 
The second chapter is a review of the literature to discuss the current working knowledge 
on papillary renal cell carcinoma including genetic underpinnings, disease management and 
histological subtyping. This chapter was designed to give clinicians a better working knowledge 
on papillary renal cell carcinoma. The results of this review highlight the importance of 
discovering discernible differences between type 1 and type 2 papillary renal cell carcinoma 
tumors. 
The third chapter is a review of the most common hereditary renal cell syndromes that 
are associated with an increased risk of developing renal cell carcinomas. This review covered 
Hereditary Leiomyomatosis and Renal Cell Cancer, a renal cancer syndrome that is characterized 
by benign neoplasms and is associated with an increased risk of developing type 2 papillary renal 
cell carcinoma. The results of this review highlighted the complex genetic nature of papillary 
renal cell carcinoma and provided the background for a variable used in the secondary data 
analysis.  
The fourth chapter describes the dissertation work and was a secondary data analysis on 
papillary renal cell carcinoma using The Cancer Genome Atlas – Cervical Kidney Renal 
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Papillary Cell Carcinoma and cBioPortal databases. The analysis focused on determining the 
epidemiological, increased risk factor and pathway preference differences between type 1 and 
type 2 papillary renal cell carcinoma. The results of this study showed that while there are some 
significant differences between tumor types, further studies are warranted.  
The final chapter is a synthesis of all the manuscripts related to papillary renal cell 
carcinoma type 1 and type 2 tumors. This chapter provides a cohesive discussion of all three 
manuscripts and provides suggestions for future research specific to type 1 and type 2 papillary 
renal cell carcinoma. The result of all three manuscripts is to better provide an understanding of 
papillary renal cell carcinoma as a disease and to define differences between type 1 and type. 
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Statement of the Problem 
Renal cell carcinoma (RCC) is among the top ten most commonly occurring cancers in 
the United States. The American Cancer Society (ACS) estimates around 74,000 new cases will 
be diagnosed and 15,000 deaths will occur from RCC in 2020 (ACS, 2020). Clear cell renal cell 
carcinoma (ccRCC) is the most common RCC subtype and as such has been the focus of the 
majority of RCC research. Specifically, known epidemiological data such as demographics and 
increased risk factors, have been based on the ccRCC subtype.   
Papillary renal cell carcinoma (PRCC) is the second most common RCC subtype 
comprising 15-20% of total RCC cases (Pal et al. 2018).  PRCC is considered a heterogenous 
disease and is further divided into multiple subtypes, with the two most common subtypes being 
type 1 and type 2.  Current PRCC research has been dedicated to determining the cellular 
molecular components of the disease, with no significant research distinguishing between type 1 
and type 2 PRCC subtypes (MacLennan & Cheng 2020: Lineman et al 2015).  However, 
research has shown that the different PRCC subtypes have varying patient outcomes. 
Specifically, type 1 tumors tend to be diagnosed at a lower grade and have a better prognosis 
than type 2 tumors. Furthermore, there are numerous genetic variations in both PRCC tumor 
subtypes that are not seen in other RCC subtypes, making traditional drug treatment therapies 
ineffective (Lineman et al 2015; Ahrens et al. 2019).  
There are significant gaps in the literature concerning other RCC subtypes in which 
researchers are striving to address. Such gaps include understanding the epidemiology, genetics 
and risk factors associated with subtypes other than ccRCC. The goal of this dissertation is to 
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expand the state of the science regarding type 1 and type 2 PRCC tumors and the genetic 
relationships.  
Papillary renal cell carcinoma (PRCC) is the second most common RCC subtype 
comprising 15-20% of total RCC cases (Pal et al. 2018).  PRCC is considered a heterogenous 
disease and is further divided into multiple subtypes, with the two most common subtypes being 
type 1 and type 2.  Current PRCC research has been dedicated to determining the cellular 
molecular components of the disease, with no significant research distinguishing between type 1 
and type 2 PRCC subtypes (MacLennan & Cheng 2020: Lineman et al 2015).  However, 
research has shown that the different PRCC subtypes have varying patient outcomes. 
Specifically, type 1 tumors tend to be diagnosed at a lower grade and have a better prognosis 
than type 2 tumors. Furthermore, there are numerous genetic variations in both PRCC tumor 
subtypes that are not seen in other RCC subtypes, making traditional drug treatment therapies 
ineffective (Lineman et al 2015; Ahrens et al. 2019).  
The aim of this research was to determine if there were significant discernible 
differences, specifically demographics, increased risk factors and genetic pathway preferences   
between type 1 and type 2 PRCC tumors. The premise for the research was to gain expanded 
knowledge of type 1 and type 2 PRCC subtypes so clinicians will be able to better identify 
patients at risk for each subtype and subsequently development appropriate evidence-based 
treatment plans.  
Significance of the Problem 
PRCC is often difficult to detect with only 5% to 10% of patients presenting with 
symptoms of hematuria, flank pain and palpable abdominal masses. Furthermore, these 
symptoms generally occur in advanced stages of the disease when kidney function has been 
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compromised (Maclennan & Cheng 2020; Diaz de Leon & Pedrosa 2018).  The other 90 to 95% 
of PRCC tumors are generally found via incidental findings during kidney imaging for other 
maladies such as hypertension or chronic kidney disease. Traditionally, tumors that are 
diagnosed early tend to be smaller, less invasive and have a better prognosis than tumors that are 
found at more advanced stages.  Additionally, PRCC type 1 tumors have higher survival rates 
and more positive outcomes as compared to type 2 tumors (Grande & Fidler 2015; MacLennan 
& Cheng 2020).  
Treatment 
Treatment options for PRCC remains limited with nephrectomy being the standard 
strategy. Typically, nephrectomy involves the partial or total removal of the kidney, which can 
results in decrease kidney function. Patients who undergo nephrectomies are at an increased risk 
of developing hypertension and chronic kidney disease (Glazar et al. 2014). Up to 20% of 
patients that undergo localized treatment or nephrectomy experience cancer reoccurrence. Even 
with the reoccurrence rates, there are concerns that partial nephrectomies are too invasive. Thus, 
surveillance is often recommended as an alternative. Recent technology advances have provided 
less invasive procedures to help maintain proper kidney function, but not all patients are suitable 
for these procedures. Currently, there are no successful adjuvant (after surgery) therapies to treat 
RCCs (Redig et al. 2019; Chien et al. 2020). Targeted treatment therapies have been found to be 
helpful in the effective treatment of RCCs. These therapies target cancer specific genes or 
proteins and is the basis of precision cancer treatment. However, current drug therapy options are 
designed for clear cell renal cell carcinoma and are not specific for treating PRCC. There are 
several clinical trials in progress but no drug therapy specific to PRCC (Redig et al. 2018; 
Dengina et al. 2017; Ahrens et al. 2019). 
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Monetary Impact 
Along with the physical impact of cancer, there is also a significant burden associated 
with RCC. Currently, the United States has an annual cost of $600 million, up to $5.2 billion US 
dollars for all cancers and the cost continues to rise. Specifically, technological advances have 
increased the cost of localized treatments and nephrectomy for RCC, which can be $20,000 to 
$50,000. The cost of nephrectomy does not include any additional treatments that may be 
needed, such drug therapies or necessary dialysis (Jeong et al. 2019; Chien et al. 2020). 
Moreover, drug treatment therapies have varying costs depending on the drug and whether the 
drug is a first line or second line treatment therapy. First line treatments can $150,000 whereas 
second line treatments cost $60,000 to $120,000. However, second line treatments are utilized in 
conjunction with first line treatments which raises their cost to approximately $350,000. 
Treatment costs increase with cancer metastasis since more aggressive treatments are needed 
(Deniz et al. 2019; Chien et al. 2020). These costs reflect the cost of the drug therapy themselves, 
and do not include doctor visits, lost wages or other costs associated with cancer treatments.  
Providing a comprehensive understanding of the epidemiology of PRCC will allow 
clinicians to distinguish between subtypes at earlier stages. Focusing on the individual risk 
factors and preferred genetic pathways displayed by each of the two subtypes supports the next 
stages of genetic research. This new avenue of research will ultimately supply vital criteria to 
develop individualized treatment plans that will lower treatment costs and increase treatment 
success rates. 
Theoretical Framework Supporting the Primary Dissertation Problem/Issue 
The theoretical framework for this research project is the integrative cancer theory. Given 
that PRCC is a heterogenous disease that encompasses a large number of genetic variations, 
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clinical and epidemiological features, the integrative cancer theory supports the research 
directive. This theory was developed from the comprehensive integrative theory, which is widely 
used in psychiatry. The integrative theory views illness, both mental and biological, as a complex 
disease that needs to be viewed at multiple angles. The theory states that looking at illness from a 
variety of perspectives will lead to more comprehensive and personalized treatment plans (Lake 
2007; Lake 2008). The integrative cancer theory specifically includes three domains: genetic 
variations, epidemiological factors and environmental risk factors. Each one of the three domains 
adds to the metabolic imbalance between host and tumor, allowing further tumor proliferation 
(Luo & Liu 2019).  By looking at PRCC as a complicated disease with multiple components in 
each domain, disease risk factors will be determined, and treatment plans will be personalized. 
The integrative theory for cancer is utilized to conceptualize cancer as a linked genetic 
disease. In this theory, chronic irritations, defined as any metabolic imbalance (including chronic 
inflammation, unstable glucose levels and lack of vital nutrients), provoke tumors with genetic 
alterations and rapid proliferative ability. These tumor cells reprogram their metabolic systems 
and employ aerobic glycolysis to sustain the rapid growth. Further proliferation occurs in 
patients with certain characteristics, such as advanced age, obesity, and diabetes (both Type I and 
Type II). These co-existing conditions trigger a metabolic imbalance between the patient and 
tumor resulting in catastrophe events of invasion, metastasis, and necrosis (Luo and Liu, 2019). 
PRCC is a genetically linked disease that encompasses multiple genetic pathways which allow 
cancer cells to override normal cell signaling.  By overriding normal cytogenetic pathways, 
PRCC tumors grow, invade surrounding tissue and kill normal cells (Maclennan & Cheng 2020). 
Therefore, PRCC as a disease follows the conceptual model presented by the integrative cancer 
theory. 
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Fig. 1.1 Integrative Cancer Theory 
This research views PRCC as a complex heterogenous disease that is not limited to one 
risk factor or genetic pathway. Furthermore, this study sought to define differences in each of the 
three domains as described in the integrative theory for cancer.  Due to the complex genetic 
nature of PRCC, genetic pathways were used to fulfil the first domain.  Cancer cells will turn off 
or increase the host and tumor metabolic imbalance on certain genes to manipulate cellular 
pathways (Luo & Liu 2019). Therefore, looking at PRCC genetic pathways sufficiently satisfies 
the conditions of the first domain.  The second (epidemiological factors) and third 
(environmental risk factors) domains were categorized as demographics and associated risk 
factors specific for to this research study. The target demographic variable included in this 
research were age, ethnicity, gender, and race. Each of these variables have the potential to 
increase the tumor/host imbalance and promote tumor development. The associated risk factors 
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examined were body mass index (BMI), smoking history, neoplasm (non-malignant tumor) 
history, and malignancy history.  The integrative cancer theory is appropriate to provide the 
framework for this dissertation since this research looks at the three domains of PRCC as 
described in the theory in an effort to identify differences between PRCC subtypes. 
An Overview of the Important Literature 
PRCC tumors are characterized by solid well-defined lesions in the renal papillae or 
tubulopapillae that are formed by a single layer of cuboidal cells (Grande & Fidler 2015; 
MacLennan & Cheng 2020). Furthermore, PRCC tumors tend to be multifocal (multiple tumors 
arise from one tumor in the same location) and necrotic (dead renal cells are present in the 
tumor). PRCC consists of multiple genetic variations and can be sporadic and hereditary 
(inherited) with most cases being the sporadic form. Hereditary PRCC is most commonly 
characterized by mutations in the oncogene Mesenchymal Epithelial Transition (MET), although 
there are multiple genetic variations associated with both sporadic and hereditary PRCC 
(MacLennan & Cheng 2020). PRCC subtypes are most frequently characterized by 
histomorphological features, although recent studies suggest using cytomorphological structures 
to better distinguish between subtypes. Type 1 PRCC tumors are defined as having a single layer 
of cells with sparse basophilic cytoplasm and small round nuclei. Conversely, type 2 PRCC is 
defined as a pseudostratified layer of cells with eosinophilic cytoplasm and large spherical nuclei 
(MacLennan & Cheng 2020; Magers et al. 2019).   
Risk factors associated with RCC are supported by current literature, though still limited 
because they focus on the ccRCC subtype. The first category of risk factors are demographics 
with certain factors associated with an increased risk for RCC. Research suggests that RCC is 
less prevalent in women with men being diagnose Men have higher prevalence, 2:1, at a lower 
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median age of diagnosis of 50-59 years compared to women. In fact, RCC risk increases with 
age within all sexes until a plateau occurs around 70 years. RCC rates vary by ethnicity/race with 
the lowest incidence seen in Asian Americans, 8.8 cases per 100,000 and the highest incidence 
seen in African Americans, 17.5 cases per 100,000 (Hsieh et al. 2019; Diaz de Leon et al. 2017; 
Howlader et al. 2020). Additionally, there are number of increased risk factors that increase an 
individual’s chance of developing RCC such as increased Body Mass Index (BMI) and the use of 
tobacco products. One study has shown that BMI and tobacco use were factors in at least half of 
PRCC cases. Smoking cessation may decrease PRCC risk but limited to those who have quit for 
ten years or longer (Hsieh et al. 2019; Diaz de Leon et al. 2017).  
There are several renal cell cancer syndromes that predispose an individual to the 
development of RCC.  Not only do these renal cell cancer syndromes provide evidence for the 
genetic variables used in this research study, many of them present with benign neoplasms. 
BRCA1 Associated Protein-1 (BAP1) tumor predisposition syndrome, Birt-Hogg-Dubé 
syndrome, and Cowden syndrome present with benign tumor growths with associated increased 
risk for developing RCC. Another example is von Hippel-Lindau syndrome, which is the most 
common renal cell cancer syndrome and characterized by variations in the Von Hippel–Lindau 
Tumor Suppressor (VHL) gene (Paquin & Fasolino 2020). Additionally, there are numerous 
genetic variations that have been associated with RCC. At least eleven genes have been linked to 
hereditary RCC including, Folliculin (FLCN), Fumarate Hydratase (FH), Phosphatase and 
Tensin Homolog (PTEN), Succinate Dehydrogenase Complex Iron Sulfur Subunit B (SDHB), 
and TSC Complex Subunit 1 (TSC1). Variations in MET have been found in as many as 20% of 
hereditary PRCC cases as well as in sporadic cases. MET variations have been seen in both type 
1 and type 2 PRCC tumors (Hsieh et al. 2019; Albiges et al. 2015). However, genetic variations 
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in RCC are not limited to genetic mutations and include chromosomal copy number variations. 
Type 1 PRCC shows copy number gains in chromosome 7, whereas type 2 PRCC show losses in 
chromosome 9 (Modi & Singer 2016). Due to the large number of genetic variations, utilizing 
genetic pathways may be a more efficient process for comparing type 1 and type 2 PRCC instead 
of genetic sequencing. Utilizing genetic pathways will cover a larger number of genes allowing 
the treatment of more patients at once and decreasing cost.  
Three manuscripts have been submitted to fulfill the specific aims of this research 
project. Collectively, the three manuscripts offer a comprehensive view of the differences 
between type 1 and type 2 PRCC. The target audiences for these manuscripts have been direct 
patient care clinicians, healthcare clinicians who directly provide patient care,  in order to 
advance their knowledge of the differences in epidemiology, risk factors and genetic pathways 
associated with type 1 and type 2 PRCC. The following offers detailed information on the three 
papers:  
The first manuscript (Chapter 2) is entitled “Papillary Renal Cell Carcinoma: 
Epidemiology, Subtype Classification, and Various Genetic Pathways of the Disease” (Under 
Review).  Papillary renal cell carcinoma (PRCC) is a subset of renal cell carcinoma (RCC). 
PRCC is a heterogenous disease that consists of multiple subtypes, diverse genetic makeups, and 
a continually changing epidemiology. Similarly, the management of PRCC reflects the 
complexity of the disease. Clinicians should possess a basic knowledge of the subtype 
classification, genetic pathways and epidemiology of PRCC in order to develop effective 
management plans. This paper presented the current applicable knowledge of PRCC as it relates 
to healthcare clinicians (Paquin & Fasolino, under review). 
10 
The second manuscript (Chapter 3) is entitled “Renal Cell Cancer Syndromes: 
Identification and Management of Patients and Families at Increased Risk” (Paquin & Fasolino 
2020). There are many inherited renal cancer syndromes that increase an individual’s risk of 
developing renal cell cancer (RCC). The major autosomal dominantly inherited RCC syndromes 
include: von Hippel-Lindau syndrome (VHL); Lynch Syndrome/ Hereditary Non-Polyposis 
Colorectal Cancer (HNPCC); Tuberous Sclerosis Complex (TSC); Birt-Hogg-Dubé Syndrome 
(BHD); Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC); Cowden Syndrome; and 
BAP1 Tumor Predisposition Syndrome. The age of onset for these RCC syndromes range from 
infancy through 65 years. Clinical manifestations vary widely, and multiple body systems can be 
involved and present unique challenges to the healthcare team. With the advancement of genetic 
panels, clinicians can screen individuals with known hereditary syndromes for genetic mutations.  
This paper presented clinically relevant information on specific to the major renal cancer 
syndrome focusing on the gene mutation, incidence, and clinical implications (Paquin and 
Fasolino 2020). 
The third manuscript (Chapter 4) is entitled Comparison of Papillary Renal Cell 
Carcinoma Type 1 and Type 2: A Secondary Data Analysis using The Cancer Genome Atlas” 
(under review). This manuscript is a secondary data analysis using The Cancer Genome Atlas 
Kidney Renal Papillary Cell Carcinoma (TCGA-KIRP) and cBioPortal data to determine if there 
were significant differences between type 1 and type 2 PRCC tumors. Demographic, increased 
risk factor and preferred genetic pathway data were determined for each PRCC tumor type.  
Then a logistic regression was performed on each variable to determine the probability of that 
variable being exhibited by type 2 PRCC tumors. This study found that higher age at diagnosis 
was statistically more likely to be associated with type 2 tumors. Furthermore, type 2 tumors 
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were found to prefer the PI3K pathway. Being African American had a negative association with 
type 2 tumors. No increased risk factor variable was found to be significant, however further 
research is needed to better understand how these variables can be used in determining tumor 
subtype (Paquin et al., under review).  
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Papillary Renal Cell Carcinoma: Epidemiology, subtype classification, and various genetic 
pathways of the disease. 
Overview 
Papillary renal cell carcinoma (PRCC) is a subset of renal cell carcinoma (RCC). PRCC 
is a heterogenous disease that consists of multiple subtypes, diverse genetic makeups, and a 
continually changing epidemiology. Similarly, the management of PRCC reflects the complexity 
of the disease. Clinicians should possess a basic knowledge of the subtype classification, genetic 
pathways and epidemiology of PRCC in order to develop effective management plans.  
Keywords: Papillary renal cell carcinoma, cancer treatment, cancer genetics 
Introduction  
Renal cell carcinoma (RCC) is the 14th most common cancer type worldwide with 
approximately 430, 262 new cases and 175,098 deaths in 2018 (WHO, 2020). Papillary renal cell 
carcinoma (PRCC) comprises 15-20% of all RCCs and is the second most common RCC 
subtype. PRCC is largely considered a heterogenous disease given the histologically and 
genetically distinct subtypes that vary in prognosis and disease progression. This heterogeneity 
makes it difficult to diagnose and manage with approximately 20-50% of tumors being 
discovered incidentally (Fernandes & Lopes 2015; Steffen et al. 2012). Mostly, PRCC is divided 
into two subtypes, type 1 and type 2 (Pal et al. 2019). The aim of this paper is to provide the 
clinician with an overview of PRCC inclusive of the epidemiology, subtype classification, and 
various genetic pathways of the disease so that an appropriate management plan can be created.  
Staging & Grading 
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Typically, renal cancer is asymptomatic and any symptoms that occur are generally 
attributed to other kidney diseases. Currently, 20-50% of PRCC tumors are discovered through 
incidental findings (Fernandes & Lopes 2015; Steffen et al. 2012). Similarly, distinguishing 
between type 1 and type 2 tumors can be difficult as well given the heterogeneity (Fernandes & 
Lopes 2015; Modi and Singer 2015). Type 1 tumors are diagnosed at a younger age compared 
with type 2 tumors. Additionally, type 2 tumors present with a poorer prognosis than type 1 
tumors (Ahrens et al. 2019). 
Tumor stage is a key prognostic parameter in cancer diagnosing. The most common 
staging system is TNM where each tumor is given a letter and a number stage.  In the TNM 
system the T represents the size and extent of the main or primary tumor. Similarly, the N 
represents the extent of lymph node involvement and lastly the M represents the extent of 
metastasis. The letters representing the aforementioned TNM and the numbers range from 0 
(cannot be found) to 3 or more (the higher the number the larger the tumor, the greater the 
number of involved lymph nodes and the greater the metastasis). If there is an x after the letter 
then the tumor cannot be found (National Cancer Institute, 2020; Table 1. TNM Staging 
System).  However, tumors can also be staged in five less descriptive categories. Stage I tumors 
are confined to the kidney and less than 7.0 cm in size. Stage II tumors are also confined to the 
kidney but are greater than 7.0 cm with no spread to lymph nodes or distant organs. Stage III 
tumors have spread into the lymph nodes adjacent to the kidney or large vessels but no invasion 
in adjacent organs or distant metastasis. Lastly, Stage IV tumors have invaded adjacent organs 
and possibly distant metastases. spread to lymph nodes and possibly distant organs (National 
Cancer Institute, 2020).  
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The grading schema of RCC is based on the microscopic morphology of a neoplasm with 
hematoxylin and eosin (H&E) staining. The most popular and used widely system for grading 
RCC has been a nuclear grading system described in 1982 by Fuhrman et al (1982), which 
concurrently evaluates nuclear size and shape, and nucleolar prominence. Grade one tumors have 
round small nuclei (<10 micrometers) with small smooth nuclear contours and either absent or 
inconspicuous nucleoli. Grade two tumors have slightly larger (15 micrometers) and irregular 
nuclei with small not easily visible nucleoli. Grade three tumors have large (20 micrometers) 
nuclei with prominent nucleoli (Cornejo et al. 2015). Lastly, grade four tumors have the largest 
(> 20 micrometers) nuclei, with macro-nucleoli that have multi-lobation that exhibit 
pleomorphism (Table 2. PRCC Fuhrman Nucleolar Grading System).  
There are some criticisms of the Fuhrman Grading System, primarily the lack of 
inclusion of recent subtypes of RCC. The grading system is designed so that each parameter will 
increase in parallel and as each parameter increases, so will the tumor grade. However, studies 
have shown that the importance of nuclear shape and tumor prognosis varies with RCC subtype. 
Another limitation of the grading system is the lack of guidance as to which parameter should be 
prioritized in variances (Delahunt et al. 2016). The initial results from the original study that 
produced the Fuhrman Grading System have been difficult to replicate. Also, there is wide 
variation among tumors within each tumor grade, further adding to the difficult reproducibility 
(Delahunt el al. 2016). Considering there are no concrete alternatives, the Fuhrman Grading 
System still remains the most widely used grading for RCC tumors.  
Epidemiology of PRCC 
The demographic variables associated with PRCC are under investigation. Therefore, the 
risk factors and epidemiology associated with PRCC are umbrellaed under the more general 
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RCC. In general, RCC is twice as likely to occur in men than women. In fact, RCC is the 6th 
most common cancer in men and 8th in women (Fernandes & Lopes 2015). The reasoning behind 
the disparity is unclear but current theory attributes the increased likelihood to environment 
exposures in the workplace. There are also a number of medical conditions that increase the risk 
of renal cancer. Obesity, especially caused by a diet rich in fat, increases renal cancer risk. Other 
conditions such as high blood pressure also may increase risk, although it is unclear if the 
condition itself increases the risk or the medication (specifically diuretics). However, no specific 
antihypertension drug has been linked to RCC, leading researchers to believe that hypertension is 
the risk factor. However, it is unclear if RCC tumors are responsible for the development of high 
blood pressure (Fernandes & Lopes 2015; Woldu et al. 2014). 
More recent studies that have focused specifically on PRCC have shown that ethnicity 
plays a role in the prognosis and treatment of PRCC with African Americans having poorer 
survival rates compared to Caucasians (Paulucci et al. 2017). Similarly, given the genetic 
heterogeneity of PRCC, a wide range of age groups are expected to be affected. Individuals with 
hereditary papillary renal cell carcinoma generally develop PRCC type 1 tumors around the age 
of 50 (Fernandes & Lopes 2015). Conversely, individuals with known Hereditary 
Leiomyomatosis and Renal Cell Cancer (HLRCC), may develop PRCC type 1 tumors between 
the age of 18 and 50, with an average age of 25 (Skala, Dhanaesekaran, & Mehra, 2018). 
Furthermore, there is strong evidence that end stage renal disease (ESRD) is a strong risk factor 
for developing PRCC. Studies have also shown that renal insufficiency, either chronic or 
episodic renal failure, are corelated to an in increased risk of PRCC (Fernandes & Lopes 2015; 
Woldu et al. 2014). 
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There are a number of disorders that increase an individual’s risk of developing PRCC. 
von Hippel-Lindau disease is the most common inherited disorder that is associated with renal 
tumor development. Individuals with von Hippel-Lindau disease have a 40% risk of developing 
renal tumors. von Hippel-Lindau disease is an inherited disorder characterized by the formation 
of tumors and fluid-filled sacs (cysts) and VHL gene mutation. However, the loss of VHL 
function is not sufficient to develop malignant tumors (Gupta et al. 2017; Gossage et al. 2013).  
Likewise, HLRCC also known as Reed’s Disease, has been linked with the development of 
PRCC type 2. HRLCC is an autosomal dominant condition in which individuals are at risk for 
developing cutaneous leiomyomas, early onset multiple uterine leiomyomas, uterine fibroids and 
PRCC type 2. The link between HRLCC and PRCC type 2 is found with fumarate hydratase 
(FH) gene mutation. The FH gene codes for a critical Krebs cycle protein allowing the cell to 
utilize oxygen to produce energy. FH mutation leads to cellular hypoxia which in turn leads to 
tumor development (Skala, Dhanaesekaran, & Mehra, 2018).  
Similarly, individuals with hereditary papillary renal cell carcinoma (HPRCC) disorder 
have germline MET mutations and therefore have a higher risk for PRCC type 1 tumor 
development. In fact, according to some estimates, individuals with HPRC have an almost 100% 
risk of developing PRCC type 1. Although individual’s with HPRC have a greater risk of 
developing PRCC, HPRC itself is a rare disorder (Haas and Nathanson, 2014). Interestingly, 
individuals with a sibling who has a history of renal cancer (without having any of the previously 
listed disorders) have a higher risk of developing renal cancer, including PRCC (Fernandes & 
Lopes 2015).  
Subtypes and Clear Cell Papillary Renal Cell Carcinoma 
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An aspect of management is understanding the different subtypes associated with PRCC 
given each subtype utilizes different diagnostic and treatment plans (Figure 1: Visual breakdown 
of renal cell carcinoma subtypes). There are two main subtypes of PRCC, type 1 and type 2, and 
are generally accepted as distinct enough to be defined given the heterogeneity. PRCC type 1 
tumor morphology is seen in sporadic and hereditary forms of PRCC.  PRCC type 1 tumors are 
histologically characterized by having a single layer of small cells with sparse, basophilic 
cytoplasm and small oval nuclei that cover renal papillae or tubules (Marsaud et al 2015; 
Prochazkova et al. 2018).  
In contrast, PRCC type 2 is generally more heterogenous and comprises less than a third 
of PRCC cases (Marsaud et al 2015; Prochazkova et al. 2018). PRCC type 2 tumors are 
histologically characterized by large pseudostratified cells that have a large spherical nucleus 
with prominent nucleoli and eosinophilic cytoplasm that cover the renal papillae (Yin et al. 
2015).  If a tumor presents with a combination of type 1 and type 2 histological features, it would 
be classified by the most predominant subtype. Similarly, if a tumor has an approximately equal 
amount of type 1 and 2 features are classified as mixed (Sukov et al. 2011).   
Recently, clear cell renal cell carcinoma (ccPRCC) has been recognized as a third 
subtype of RCC. ccPRCC is histologically characterized by small to medium sized cuboidal cells 
with ample cytoplasm that cover the renal papillae (Wang et al. 2020). ccPRCC shares similar 
features with both PRCC and clear cell carcinoma but is distinct enough and does not fall under 
either RCC subtype. For instance, ccPRCC tumors are surrounded by a fibrous capsule with both 
papillary and clear cell morphology. Furthermore, ccPRCC tumors can appear to be densely 
packed due to papillae branching (Morlote et al. 2019). ccPRCC is similar to PRCC in that 
individuals are asymptomatic and tumors are found through incidental findings. Thus far 
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ccPRCC can be found individuals of all ages with no race or age predilection. ccPRCC tumors 
have favorable prognosis with low metastasis and reoccurrence rates. Similarly, if ccPRCC are 
found early they may be managed with increased surveillance or minimal surgical means (Zhao 
and Eyzaguirre, 2019). Although ccPRCC is not a subtype of PRCC, the name can be misleading 
and it is important to recognize ccPRCC as distinct subtype of RCC.  
Genetic Underpinning  
In order to understand PRCC subtypes, an overview of the various genetic pathways 
involved in tumor development is necessary. Given the heterogenous state of PRCC, a number of 
genetic pathways exist and present as both sporadic (no inherited genetic changes) and hereditary 
(inherited genetic changes) depending on the type of mutation exhibited in the tumor. Evidence 
suggests that type 1 and type 2 tumors arise from a similar cytogenic pathway. Type 1 tumors 
show significantly more gains in chromosomes 7p and 17p as compared to type 2 (Modi and 
Singer 2015). Chromosomal gain or loss is significant in cancer cells because this allows for 
tumor development by either gaining additional copies of oncogenes (tumor promoting) or losing 
copies of tumor suppressor genes. Type 2 tumors are more genetically diverse compared to type 
1 tumor and there are theories that type 2 tumors evolved from type 1 tumors after acquiring 
more genetic mutations (Marsuad et al. 2015).  
There are a number of genetic changes associated with PRCC type 1 tumors, either 
sporadic or inherited. Approximately 20% of PRCC type 1 tumors are associated with mutations 
of the protooncogene (a normal gene that when mutated becomes an oncogene) mesenchymal 
transition factor (MET). The MET gene codes for the protein c-MET, which is a tyrosine kinase 
receptor (RTK) protein. RTK proteins play a diverse role in the regulation of multiple cellular 
processes including differentiation, proliferation and the regulation of the cell cycle (Albiges et 
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al. 2014). Changes in MET generally allow for the continued growth and migration of cancerous 
cells, which in turn increases tumor growth and invasion into healthy tissue.  Hereditary PRCC 
stems from a gain of chromosome 7, that contains a non-random mutated copy of the MET gene, 
which results in the overexpression of the c-MET protein. Given that hereditary PRCC is rare, 
familial non-random MET mutations are uncommon (Yin et al. 2015). Conversely, although 
some studies suggest that MET mutations are found in approximately 13% of sporadic PRCC 
type 1 tumors, it is believed that MET mutations do not play a major role in the development of 
these tumors (Marsuad et al. 2016). Other studies have correlated gains of chromosome 17p with 
type 1 tumors. There are several oncogenes that are located on chromosome 17p including 
HER2, TOP2A and TAU. Additionally, 17p houses the tumor suppressor genes p53, BRCA1 and 
HIC-1. The genes located on 17p have been linked to the initiation of tumor growth, tumor 
progression, and tumor response to drug therapy. HER2 and TAU overexpression are correlated 
with poor chemotherapy response and poor prognosis. TOP2A is involved with DNA replication 
and TOP2A overexpression has been linked to tumor proliferation (Yu et al., 2013).  Likewise, 
p53 plays a critical role in tumor suppression and DNA repair, serving as a check point gene that 
induces apoptosis when critical nonrepairable DNA errors are found. When p53 mutations occur, 
DNA instability and unchecked cell proliferation occur. BRCA1 is similar to p53 in that it plays a 
role in DNA regulation and repair. HIC-1 mutations are generally found in conjunction with p53 
to inhibit apoptosis (Yu et al., 2013). 
Type 2 tumors have been associated with a mutation in the tumor suppressor gene, 
fumarate hydratase (FH). In healthy cells, FH acts as a catalyst for the conversion of fumarate 
into malate during the Krebs cycle. PRCC type 2 FH mutations inactivate the FH protein causing 
an accumulation of fumarate.  The accumulation of fumarate then activates hypoxia inducible 
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factor (and associated genes), which prompts the activation of other genes that increase tumor 
cell survival and proliferation (Gardie et al. 2011). Additionally, mutations in the vascular 
endothelial growth factor (VEGF) gene, specifically amplification, promote angiogenesis and 
cellular migration. Furthermore, PRCC type 2 has been associated with a loss of chromosome 3 
and 14.  Chromosome 3 is the home for several tumor suppressor genes including, VHL which 
plays a role in angiogenesis regulation. When VHL is suppressed hypoxia-inducible factor is 
allowed to go unchecked which in turn leads to angiogenesis. Likewise, chromosome 14 houses 
genes that are responsible for cellular regulation and apoptosis (Modi and Singer 2015: TCGA, 
2016: Marsuad et al. 2015).  Some studies have associated gains of chromosomes 7 and 17 with 
type 2 tumors but to a lesser extent than type 1 (Yu et al., 2013). 
Sporadic PRCC type 1 and type 2 share a number of genetic variations.  For instance, 
chromosome 17 gain has a high association with sporadic PRCC and is rarely found in non-renal 
cancers (Marsuad et al. 2016). Specifically, a duplication of the 17q21 region, which contains the 
oncogene HER2, was found to be associated with a large number of sporadic PRCC tumors 
(Marsuad et al. 2016; Banumathy and Cairns, 2014). Allelic loss (loss of a specific gene 
variation) has also been associated with sporadic PRCC tumor development, specifically loss of 
the 7q31 region which contains the aphidicolin-inducible fragile site (FRA7G). The FRA7G site 
contains the tumor suppressor genes, CAV1, CAV2 and TESTIN. Fragile sites such as FRA7G, 
aid in tumorigenesis because they are easily susceptible to breakage, leading to chromosomal 
translocation, deletion or amplification. Similarly, duplication of chromosome 20 and loss of 
chromosome 9p are also common in sporadic PRCC tumors (Modi and Singer 2016; Marsuad et 
al. 2016; Banumathy and Cairns 2014). Research is ongoing to determine what other genetic 
factors play a role in PRCC tumor development.  
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Management 
There are a limited number of treatment options available for PRCC. Traditional 
treatment therapies are targeted towards clear cell renal cell carcinoma and are generally 
unsuccessful treating PRCC. Currently, nephrectomy is the most effective treatment option for 
PRCC tumors regardless of tumor stage. Likewise, partial nephrectomy is the preferred treatment 
choice since this option is nephron sparing and there are no after surgery treatment options 
available (Dengina et al. 2017). Individual’s with advanced PRCC, characterized as stage 3 or 
greater, are recommended to seek out clinical trials. Clinical trials are generally focused on 
inhibiting specific cellular molecular pathways that are used by cancerous cells. Currently, the 
m-TOR inhibitors, temsirolimus and everolimus, have proven more effective on non-clear cell
renal cell carcinomas (including but not limited to PRCC) as compared to interferon -α. 
Similarly, smaller clinical trials with the VEGF inhibitor, sorafenib, has shown efficacy treating 
PRCC. Efficacy was measured in progression free survival (PFS) and was shown to be 8.5 
months for sorafenib as compared to 5.6 months for everolimus. Conversely, MET and EGFR 
inhibitors, such as erlotinib, have not yet proven to be an effective treatment option for PRCC. 
Current clinical trials do not differentiate between all the various types of non-clear cell 
carcinomas and therefore no treatment can be specified for PRCC (Ahrens et al. 2019).  
A new treatment option immune check point therapy, which has been shown to be 
effective for clear cell carcinoma, is currently undergoing research for PRCC. Immune check 
point therapy works to block proteins from binding with their receptors that would inhibit 
immune cell activation. Thus, allowing the activation of immune cells such as T-cells to kill 
cancerous cells. However, as of now, PRCC is treated the same as clear cell carcinoma or with 
nephrectomy (Ahrens et al. 2019; Tsimafeyeu et al. 2017).  
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Conclusion 
PRCC is a complicated disease that consists of multiple subtypes and genetic pathways. It 
is important for clinicians to have a basic understanding of PRCC in order to develop effective 
personalized management plans. Furthermore, since PRCC remains difficult diagnose, clinicians 
should be able to recognize at risk individuals. As research continues on PRCC, new 
management techniques will be developed, having knowledge on the mechanism of the disease 
will allow clinicians to provide the best individualized care possible.  
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T (Tumor) N (Lymph node 
involvement)  
M (Metastasis) 
X Cannot be measured Cannot be measured Cannot be measured. 
0 Cannot be found Cannot be found Has not spread. 
>1 Size and extent of 
main tumor. A larger 
number indicates 
greater size or 
infestation of 
surrounding tissue.  
Number and location 
of involved lymph 
nodes. The higher the 
number, the more 
lymph nodes involved. 
Has spread to other 
parts of the body.  
Table 2.1. TNM Staging System (National Cancer Institute, 2020) 
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Tumor Grade Size and Shape of Nuclei Tumor Size Tumor Location 
1 round small nuclei (<10 
micrometers) with small smooth 
nuclear contours and either absent 
or inconspicuous nucleoli 
confined to the 
kidney  
less than 7 
centimeters across 
2 slightly larger (15 micrometers) 
and irregular nuclei with small 
not easily visible nucleoli 
confined to the 
kidney  
larger than 7 
centimeters across 
3 large (20 micrometers) nuclei 
with prominent nucleoli 
surrounding 
tissues or major 
veins but no 
lymph nodes 
larger than 7 
centimeters across 
4 largest (> 20 micrometers) nuclei, 
with macro-nucleoli that have 





larger than 7 
centimeters across 

















Type 1 7p, 17p, 20 9 MET 7q31 17q21 






Table 2.3. PRCC Genetic Variation Summary Table (Banumathy and Cairns, 2014Modi and 
Singer 2015; Marsuad et al. 2015; Yin et al. 2015; Yu et al., 2013) 
34 
Chapter III 
Genetic Manifestations of Hereditary Renal Cancer: Identification and Management of 
Patients and Families at Increased Risk 
Melissa Paquin, PhD(c) mpaquin@clemson.edu 
Tracy Fasolino, PhD, FNP-BC, ACHPN tfasoli@clmeson.edu 
Overview: There are many inherited renal cancer syndromes that increase an individual’s risk of 
developing renal cell cancer (RCC). The major autosomal dominantly inherited RCC syndromes 
include: von Hippel-Lindau syndrome (VHL); Lynch Syndrome/ Hereditary Non-Polyposis 
Colorectal Cancer (HNPCC); Tuberous Sclerosis Complex (TSC); Birt-Hogg-Dubé Syndrome 
(BHD); Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC); Cowden Syndrome; and 
BAP1 Tumor Predisposition Syndrome. The age of onset for these RCC syndromes range from 
infancy through 65 years. Clinical manifestations vary widely, and multiple body systems can be 
involved and present unique challenges to the healthcare team. With the advancement of genetic 
panels, clinicians can screen individuals with known hereditary syndromes for genetic mutations.  
This paper will present clinically relevant information on specific to the major renal cancer 
syndrome focusing on the gene mutation, incidence, and clinical implications.   




Individuals with inherited renal cancer syndromes develop kidney cancer at an earlier age 
with notable features of heterogeneous, multifocal, and bilateral tumors. Several of the 
syndromes have renal cell cancer (RCC) as a primary feature, including von Hippel-Lindau and 
Birt-Hogg-Dubé syndrome, whereas others, such as Lynch syndrome and Cowden syndrome, 
have RCC as a secondary feature. Most hereditary renal cancer syndromes are autosomal 
dominant, meaning that only one copy of the mutated gene is needed to present to express the 
disease. The mutated gene predisposes affected individuals to tumor development often with 
early onset malignancy (da Costa et al. 2017).  Children of parents with autosomal dominant 
diseases have a 50% chance of inheriting the syndrome.  Each hereditary renal cancer syndrome 
manifests with different clinical symptoms and is correlated with varying risks of developing 
RCC. This paper will present clinically relevant information of hereditary renal cancer 
syndromes associated with RCC with a focus on the incidence, background and clinical 
implications (Table 1).   
Von Hippel-Lindau Syndrome 
Von Hippel-Lindau (VHL) syndrome, is the most common hereditary renal syndrome. It 
is characterized by visceral cysts and benign tumors that have the potential to become malignant. 
In fact, individuals with VHL have a 40% chance of developing RCC (Gupta et al. 2017). 
However, the loss of VHL gene function alone is not enough for patients to develop RCC. Other 
gene mutations in conjunction with VHL, including BAP1, PBRM1, JARID1c, SETD2, and 
KDM6A, have been found in patients with RCC, indicating that multiple gene mutations are 
involved with RCC development (Gossage et al. 2013). More recently, SDHB and TMEM127 
alterations have been linked to VHL mutations but their connection to RCC is unclear. (Gupta et 
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al. 2017). Further research is necessary to determine the exact relationship between SDHB, 
TMEM127, VHL and RCC.  
Lynch Syndrome (LS)/Hereditary non-polyposis colorectal cancer (HNPCC) 
LS, synonymous with HNPCC, is a condition that predisposes individuals to increased 
risk of colorectal cancer (CRC), endometrial cancer, upper tract urothelial cancers, and other 
types of cancers. (Lynch et al. 2015). A number of germline mutations are associated with LS, 
specifically in the mismatch repair genes (MMR). These genes are responsible for correcting 
mismatched nucleotides when DNA is copied in preparation for cell division. Germline 
mutations in the MSH2, MSH6, MLH1 and PMS2 genes (members of the MMR gene family) are 
the most common cause of LS (Ziada-Bouchaar et al. 2017). Furthermore, deletions in the 
EPCAM gene, a gene that codes for a cell adhesion protein, can result in silencing of the MSH2 
gene, which can lead to EPCAM-associated Lynch Syndrome. 
Tuberous Sclerosis Complex (TSC) 
TSC is a rare, multisystem disease characterized by multiple benign tumors found in the 
brain, spinal cord, kidneys, heart, and other areas due to mutation in the tumor suppression 
genes, TSC1 or TSC2. Each of these genes code for proteins involved in cell proliferation. 
Typically, individual’s with TSC present with benign renal tumors (Leech et al. 2018). However, 
when both copies of the gene are mutated, an individual has a greater chance of developing 
malignant renal tumors 
Birt-Hogg-Dube Syndrome (BHD) 
BHD syndrome is an extremely rare complex disorder characterized by deletion of the 
folliculin gene (FCLN) (Centini et al. 2018). The FLCN gene transports instructions to produce 
folliculin, a protein whose precise function is not known but seems to interact with proteins 
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involved in cell growth, energy production, and metabolism. As a tumor suppressor gene, FLCN 
gene aids in apoptosis but mutations predispose individuals to cancer development 
Hereditary Leiomyomatosis Renal Cell Carcinoma (HLRCC)  
HLRCC, otherwise known as Reed’s syndrome, is a syndrome characterized by the 
presence of one or more of the following: cutaneous leiomyomas (average age of occurrence is 
25), uterine leiomyomas/fibroids (average age of occurrence is 30), and renal cell cancer (RCC) 
(National Cancer Institute, 2019). The pattern of renal cancer in HLRCC differs from other 
inherited renal cancer syndromes in that the tumors tend to be solid, unilateral, and more 
aggressive (Skala, Dhanaesekaran, & Mehra, 2018). HRLCC is caused by a germline mutation in 
the FH gene, which codes for an enzyme that catalyzes the conversion of fumarate into L-malate 
during the Krebs Cycle (Valencia et al. 2017). Fumarase, or fumarate hydratase, allows the cells 
to use oxygen and generate energy. Excesses of fumarate may interfere with cellular oxygen 
levels, yielding chronic hypoxia leading to tumor formation and tendency to develop 
leiomyomas and RCC.  
Cowden Syndrome 
Cowden Syndrome (CS) is a relatively rare condition that predisposes individuals to 
developing renal tumors and is characterized by multiple, noncancerous growths (called 
hamartomas) at various sites of the body. Nearly all patients with CS will present with benign 
growths on the skin, mouth and along the inner lining of the gastrointestinal tract by the end of 
their 20s (Eng, 2016).  Mutations in four different genes, PTEN, SDHB, SDHD, and KLLN, have 
been identified in people with CS. Of interest is the tumor suppressor gene, PTEN, which codes 
for a protein involved in cell proliferation (Breuksch et al. 2018). Additionally, SDHB-B and 
KLLN have been found to contribute to CS even in the absence of a PTEN mutation. However, 
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individuals with a KLLN mutation have a higher risk of developing RCC as compared to 
individuals with a SDHB-B mutation. Currently, testing for the KLLN mutation is not readily 
available (Mahdi et al. 2015).  
Implications for Nurses 
Hereditary renal cancer syndromes account for approximately 5% of all kidney cancers, 
though this number is probably underestimated (Kallinikas et al, 2017). The number of families 
identified with hereditary conditions leading to RCC continues to increase as germline genetic 
testing is being utilized more frequently. As presented, RCC can either be a major or a minor 
feature of the cancer susceptibility syndrome. However, RCC is not limited to hereditary renal 
cancer syndromes or the gene mutation discussions. In fact, mutations in the MET, MITF, and 
SDH genes also have a strong association with an increased risk of RCC.  
Early age of onset, unusual or pathognomonic pathology, and multiple tumors in a patient 
with renal cancer raises concern for hereditary renal cancer syndromes. Accurate, ongoing, and 
complete assessment of family history is the first step in identifying individuals who may be at 
risk for hereditary renal cancer syndromes. Nurses need to inquire about the type of kidney 
cancer as well as the presence of other indicators of hereditary risk particularly dermatologic and 
other unusual findings. Families with unusual histories should be referred for further evaluation 
and possible genetic testing to credentialed genetics professional.  
The identification of known mutation carriers enables the implementation of aggressive 
and often complex surveillance in those likely to benefit and prevents unnecessary aggressive 
surveillance in those who do not have an inherited risk. The complexity of screening for those 
with hereditary risk requires regular coordination. Surveillance and prevention recommendations 
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should be reviewed annually by genetics professional to verify that they are still current and 
evidence based.  
Known carriers may have concerns and dilemmas about reproduction and the possibility 
of passing a mutation to offspring. These individuals often require ongoing psychosocial support 
to manage the consequences of their genetic predisposition. Oncology nurses can offer support to 
these individuals and families and refer them to resources (see Figure 1). 
Conclusion 
Management of individuals with hereditary polyposis syndromes demands accurate 
assessment of patients’ personal and family history, referral for genetic evaluation and testing, 
and implementation of complex surveillance plans to ultimately decrease the morbidity and 
mortality associated with these syndromes. Oncology nurses play an integral role in supporting 
these patients and families as they manage the complexities of their diagnoses and ongoing care. 
Nursing Implications 
1. Renal cell cancer syndromes are autosomal dominant and increase an individual’s risk of
developing renal cell cancer and other malignancies.
2. The age of onset for renal cell cancer ranges from infancy through 65 years with a wide
range of clinical manifestations that include benign and malignant histology.
3. Heightened surveillance and pre-emptive management of individuals with known renal
cell cancer syndromes can improve outcomes and quality of life.
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Resources for Hereditary Cancer Syndromes 
General Resources 
• Kidney Cancer Association   www.kidneycancer.org
• National Cancer Institute – Genetics of Kidney cancer
https://www.cancer.gov/types/kidney/hp/kidney-genetics-pdq#_362_toc
Birt Hogg Dube 
• National Library of Medicine Genetics Home
Reference  https://ghr.nlm.nih.gov/condition/birt-hogg-dube-syndrome
• Genetic and Rare Disease Center https://rarediseases.info.nih.gov/diseases/2322/birt-
hogg-dube-syndrome
• Gene Reviews: https://www.ncbi.nlm.nih.gov/books/NBK1522/
• BHD Foundation:  https://www.bhdsyndrome.org/
Von Hippel Lindau 
• National Library of Medicine Genetics Home Reference
https://ghr.nlm.nih.gov/condition/von-hippel-lindau-syndrome
• Genetic and Rare Disease Center: https://rarediseases.info.nih.gov/diseases/7855/von-
hippel-lindau-disease
• National Institute of Neurological Diseases and Stroke
https://www.ninds.nih.gov/Disorders/All-Disorders/Von-Hippel-Lindau-Disease-VHL-
Information-Page
• Gene Reviews https://www.ncbi.nlm.nih.gov/books/NBK1463/
• VHL Alliance: https://www.vhl.org/
Lynch Sydrome 
• National Library of Medicine Genetics Home Reference
https://ghr.nlm.nih.gov/condition/lynch-syndrome
• Genetic and Rare Disease Center https://rarediseases.info.nih.gov/diseases/9905/lynch-
syndrome
• Gene Reviews  https://www.ncbi.nlm.nih.gov/books/NBK1211/
• Lynch Syndrome International: https://lynchcancers.com/
Tuberous Sclerosis Complex 
• National Library of Medicine Genetics Home Reference
https://ghr.nlm.nih.gov/condition/tuberous-sclerosis-complex
• Genetic and Rare Disease Center:
https://rarediseases.info.nih.gov/diseases/7830/tuberous-sclerosis
• Gene Reviews https://www.ncbi.nlm.nih.gov/books/NBK1220/
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• Tubular Sclerosis Complex https://www.tsalliance.org/
Hereditary Leiomyomatosis Renal Cell Carcinoma 
• National Library of Medicine Genetics Home Reference
https://ghr.nlm.nih.gov/condition/hereditary-leiomyomatosis-and-renal-cell-cancer
• Genetic and Rare Disease Center:
https://rarediseases.info.nih.gov/diseases/10096/hereditary-leiomyomatosis-and-renal-
cell-cancer
• HLRCC Family Alliance http://hlrccinfo.org/
Cowden Syndrome 
• National Library of Medicine Genetics Home Reference
https://ghr.nlm.nih.gov/condition/cowden-syndrome
• Genetic and Rare Disease Center
https://rarediseases.info.nih.gov/diseases/6202/cowden-syndrome
• Gene Reviews: https://www.ncbi.nlm.nih.gov/books/NBK1488/
BAP1 Tumor Predisposition Syndrome 
• National Library of Medicine Genetics Home Reference
https://ghr.nlm.nih.gov/condition/bap1-tumor-predisposition-syndrome
• Genetic and Rare Disease Center https://rarediseases.info.nih.gov/diseases/13219/bap1-
tumor-predisposition-syndrome
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Clinical Manifestations Genes Screening Surveillance 
von Hippel-
Lindau (VHL) 
1 in 36,000 
people (10,000 

















Hemangioblastomas of the eye, 
brain and spinal cord 
Pheochromocytomas 
Endolymphatic sac tumors 
RCC 
VHL Yearly physical and eye 
exams to monitor for small 
asymptomatic lesions as well 
as detect new early stage 
lesions.  
24-hour urine test for elevated
catecholamines beginning at
age 5
abdominal ultrasound (teen 
years) or magnetic resonance 
imaging (adulthood) to assess 
the kidney, pancreas, and 














cases of colon 
cancer yearly 
in the US; 3-





of onset is 
40 years 











Colonoscopy every 12 to 24 
months starting at age 20 to 
25 or two to five years before 
the youngest diagnosis of 
colon cancer in the family 
Risk reducing hysterectomy 
with bilateral 
salpingoophorectomy when 
childbearing is complete 
Esophagogastroduodenoscopy 
every 3 to 5 years starting at 
age 30.  Treatment of H 
pylori infections 
Annual urinalysis starting at 
age 30 











Infancy Numerous benign growths 
Developmental delay 
Seizures 
Lymphangioleiomyomatosis  (LAM) 




Evaluate for seizures. Obtain 
routine EEG in individuals 
with known or suspected 
seizure activity. The 
frequency of routine EEG 
should be determined by 
clinical need. 
Imaging for benign growths, 
and psychiatric evaluation 
beginning in childhood. 
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Obtain MRI of the brain 
every one to three years in 
asymptomatic persons by age 
25 
MRI of abdomen to assess for 
angiomyolipoma & renal 
cysts by age 25 every 1 to 3 
years 
Assess renal function 
(including determination of 
GFR) and blood pressure at 
least annually by age 25. 
Perform clinical screening 
(targeted history) for LAM 
symptoms including 
exertional dyspnea and 
shortness of breath at each 
clinic visit for women older 
than age 18 years or those 
who report respiratory 
symptoms. Counseling 
regarding smoking risk and 
estrogen use should be 
reviewed at each clinic visit 
for individuals at risk for 
LAM. 






200 and 600 
families 
worldwide 
Unknown Lung cysts 
Benign skin tumors: 
Fibrofolliculomas, Trichodiscomas, 
Angiofibromas, Acrochordons and 
Perifollicular fibromas 
Spontaneous pneumothorax 
Renal tumors including hybrid 
oncocytic renal cell carcinoma, 
oncocytoma, chromophobe renal cell 
carcinoma, and clear cell renal cell 
carcinoma 
FCLN Renal imaging is appropriate 
for individuals age 18 years 
or older. Yearly MRI of the 
kidneys is the optimal 
screening modality to assess 
for kidney lesions. 
Abdominal/pelvic CT scan 
with contrast is an alternative 
when MRI is not an option. 
However, the long-term 
effects of cumulative 
radiation exposure in 
individuals with BHDS is 
unknown and has not been 
studied. 


















Uterine leiomyomas (fibroids) 
Kidney cancer 
FH Annual full body 
dermatologic examination 
Annual gynecologic 
consultation is recommended 
to assess severity of uterine 
fibroids and to evaluate for 
changes suggestive of 
leiomyosarcoma. 
Yearly examination with 
abdominal MRI is 
recommended for individuals 
with normal initial baseline or 
follow-up abdominal MRI. 
MRI is preferred because of 
the potential added radiation 




Unknown Late 20s Hamartomas (benign growths) on 
the skin, mouth and gastrointestinal 
tract.  
Macrocephaly 
Trichilemmomas and papillomatous 
papules 
Benign breast, thyroid and 
endometrial diseases. 
Kidney cancer and congenital 
kidney anomalies 
 Lhermite -Dulcos Disease, autism 
spectrum disorder, intellectual 
disabilities and vascular 
abnormalities.  
PTEN 
Children (age <18 years). 
Yearly thyroid ultrasound 
from the time of diagnosis 
and skin check with physical 
examination. 
Adults. Yearly thyroid 
ultrasound and dermatologic 
evaluation. 
Women beginning at age 30 
years. Monthly breast self-
examination; annual breast 
screening (at minimum 
mammogram; MRI may also 
be incorporated) and 
transvaginal ultrasound or 
endometrial biopsy. 
Colonoscopy beginning at age 
35 years with frequency 
dependent on degree of 
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polyposis identified; biennial 
(every 2 years) 
Renal imaging (CT or MRI 
preferred) beginning at age 40 
years. 
Those with a family history of 
a particular cancer type at an 
early age. Consider initiating 
screening 5-10 years prior to 
the youngest age of diagnosis 




Unknown 20s Mesothelioma 
Uveal melanoma. 
Atypical Spitz tumors 
Melanoma 
Clear cell kidney carcinoma 
Basal cell skin cancer 
Cholangiocarcinoma 
BAP1 Yearly dilated eye 
examinations and imaging by 
an ocular oncologist 
beginning around age 11 
years for uveal melanoma 
Annual evaluation is 
recommended for late 
manifestations of 
mesothelioma, which can 
include chest pain, cough, 
fever, shortness of breath, 
dysphagia, hoarseness, weight 
loss, fever, upper body and 
face edema (chest 
mesothelioma) and abdominal 
pain, ascites, nausea, 
vomiting, and/or constipation 
(peritoneal mesothelioma). 
Annual physical examination 
is recommended to look for 
signs of pleurisy (pleural 
inflammation), peritonitis, 
ascites and/or pleural 
effusion. 
Annual full body 
dermatologic examinations 
beginning around age 20 
years 
Annual abdominal ultrasound 
examination; consideration of 
annual urinalysis and 
abdominal MRI every two 
years to monitor for renal 
cancer 
Based on information from (Colorectal Cancer Alliance, 2019; Gupta et al. 2017; Therkildsen et al. 2016; National 
Comprehensive Cancer Network, 2019; National Institute of Neurological Disorders & Stroke, 2019; Menko et al 




Renal cell carcinoma (RCC) is the 14th most common cancer worldwide and was the 
cause of 175,098 deaths in 2018 (WHO, 2020). RCC consists of numerous subtypes including 
clear cell renal carcinoma, papillary renal cell carcinoma and most recently clear cell papillary 
renal cell carcinoma. Currently, papillary renal cell carcinoma (PRCC) is the second most 
common type of RCC, after clear cell renal cell carcinoma, comprising approximately 15-20% of 
all RCC cases (Fernandes & Lopes 2015; Steffen et al. 2012). PRCC is considered to be a 
heterogeneous disease that consists of two subtypes; type 1 and type 2. PRCC subtypes are 
primarily distinguished by their histology and vary in prognosis, treatment and patient outcomes. 
Type 1 is histologically characterized by a single layer of cells with sparse basophilic cytoplasm 
and small oval shaped nuclei that are present in either the renal tubules or renal papillae. Type 1 
tumors can be associated with both hereditary and sporadic PRCC (Marsaud et al 2015; 
Prochazkova et al. 2018). Conversely, type 2 tumors are histologically characterized by large 
pseudostratified cells with eosinophilic cytoplasm with large spherically shaped nuclei that are 
present in the renal papillae. Type 2 tumors can be associated with hereditary PRCC but are 
more often associated with the sporadic form of PRCC (Yin et al. 2015). Furthermore, research 
has shown that patients with PRCC type 2 tumors are correlated with a higher rate of metastasis 
and have a lower overall survival rate compared with patients with type 1 tumors (Wong et al. 
2019).  
Research has shown that malignant tumors utilize a wide variety of genetic alterations to 
modify the normal cell cycle in order to be able to divide and grow without restrictions. These 
modifications are accomplished by altering cell signaling pathways to promote cell growth, 
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angiogenesis and obstruct apoptosis (Sanchez-Vega et al. 2018).  Considering the heterogeneous 
nature of PRCC, there are numerous genetic alterations that occur within both type 1 and type 2 
PRCC.  Approximately 20% of hereditary type 1 tumors have been associated with variations in 
the protooncogene mesenchymal epithelial transition (MET). However, sporadic type 1 tumors 
have numerous genes associations as well as chromosomal abnormalities. Type 2 tumors have 
also been correlated with a large number of genetic and chromosomal alterations (Marsuad et al. 
2016; Linehan et al. 2015).  Similarly, research has shown that renal cancers in general utilize 
several signaling pathways. The alteration of MET has been shown to activate the MAPK and 
PI3K pathways as well as other proteins involved with tumor growth (COJOCARU et al. 2015). 
However, research still needs to be done to determine if there is a preference of pathways 
specific to type 1 or type 2 PRCC tumors.  
The epidemiology and risk factors for PRCC are largely based on the broader RCC. 
However, there are certain conditions that may increase an individual’s risk of developing 
PRCC.  For instances individuals with Hereditary Leiomyomatosis and Renal Cell Cancer 
(HLRCC) have a greater chance of developing PRCC type 1. Furthermore, there is some 
evidence that suggests individuals with renal insufficiencies have a greater risk of developing 
PRCC (Paquin & Fasolino 2020; Fernandes & Lopes 2015; Woldu et al. 2014). Ethnicity has 
also been found to contribute to the risk of developing an RCC with African Americans having 
the highest incidence of RCCs in the United States. Sankin et al. (2011) found that African 
Americans had a four times greater incidence of PRCC as compared to non-African Americans 
(Hsieh et al. 2017; Sankin et al. 2011). However, research is still needed to further understand 
the risk factors specific to PRCC. Currently there are limited treatment options available for both 
types of PRCC. Presently, the standard treatment is partial or full nephrectomy. Individual’s with 
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higher grade tumors are encouraged to seek out clinical trials, which tend to be developed based 
on specific cellular molecular pathways. Similarly, the prognosis of PRCC is dependent on 
tumor type (Dengina et al. 2017; Ahrens et al. 2019). 
 Most research on PRCC has either been umbrellaed under RCC or has been focused on 
developing a basic understanding of the disease. Furthermore, there is limited research focusing 
on the differences between type 1 and type 2 PRCC tumors. Given the findings in Wong et al. 
(2019) with respect to survival rates associated with type 1 and type 2 PRCC and the fact that the 
data we collected contained overall (presumably, all-cause mortality survival times) as well as 
demographic, environmental as well as gene pathway information our research plan is four-fold. 
First, we will analyze the all-cause mortality investigate whether we see discrepancies in survival 
rates between type 1 and 2 PRCC. The second phase will consist of selecting a demographic 
(baseline) model which will identify a set of demographic variables that are likely to be 
associated with the two different types of PRCC. In the third and fourth phases we will 
investigate environmental and gene pathway associations with prevalence of the two types of 
PRCC. The overall aim of these analyses is to determine if there are significant differences 
between type 1 and type 2 PRCC that can be utilized by healthcare providers. Specifically, this 
study sought to determine if there are clinically significant differences in survival, demographics 
(age, ethnicity, gender, and race), increased risk factors (body mass index [BMI] smoking 
history, neoplasm history, and malignancy history) and preferential genetic pathways between 




This study was a secondary data analysis using data from The Cancer Genome Atlas 
Kidney Renal Papillary Cell Carcinoma (TCGA-KIRP). A review of the literature was conducted 
to determine the appropriate inclusion criteria which were: 1) PRCC tumors, 2) distinguishes 
between type 1 and type 2, 3) demographics data ,gender, race, age and ethnicity, 4) clinical data, 
prognosis, treatment, preexisting conditions, 5) increased risk factors, smoking history, BMI, 
prior neoplasms and prior malignancies and 6) genetic analysis of the tumors.  A further review 
of the literature revealed that TCGA-KIRP is the most current and appropriate dataset to use for 
this secondary data analysis. The cBioPortal for cancer genomics (cBioPortal) was also used to 
analyze the TCGA-KIRP data. 
TCGA- Kidney Renal Papillary Cell Carcinoma (KIRP) data was collected from 41 
institutions from 1996 to 2013. TCGA adheres to a strict inclusion policy for data to be included 
on the website. TCGA tumors are untreated samples that were snap frozen. Each tumor sample 
has to have a matched normal sample from the same patient which generally comes in the form 
of the patient’s blood. The tumors and subsequent molecular data are cross referenced by 
Biospecimen Core Resource (BCR) to ensure validity. Furthermore, the BCR analyzes each 
sample for pathological quality control.  This maintains that TCGA has a high-quality tumor 
samples as well as consistent molecular data (TCGA, 2020).  Additionally, each sample was 
reviewed by a panel of six experienced pathologist to in order to be classified into type 1, type 2 
or unclassified PRCC. Moreover, any samples that were pre-classified were reassessed by the 
same panel to ensure proper classification (TCGA, 2020). 
The cBioPortal is a resource that incorporates data from TCGA and other reliable 
sources, when possible, into a more researcher-friendly resource. The BCR provides an 
interactive resource that can be used for a more comprehensive secondary data analysis. For 
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example, the cBioPortal separates PRCC genetic variations into categories such as copy number 
variations and mutations. Furthermore, the cBioPortal predetermines and denotes driver genes 
through specific algorithms. Additionally, the cBioPortal allows the user to analyze specific 
genes as opposed to TCGA which only allows users to view the dataset as a whole and does not 
denote potential driver genes.  Even though the cBioPortal contains the same data as TCGA, the 
cBioPortal was used to aid in the analysis of TCGA data. 
Data Extraction 
A total of 292 cases were available on the listed datasets. The first step in evaluating the 
dataset was determining the clinical and demographic data. TCGA contains a manifest that 
includes all relevant clinical, demographic and environmental data. This manifest was 
downloaded and converted into an Excel file. Once retrieved the dataset was combed and 
irrelevant data was eliminated from the dataset. Irrelevant data included data categories with n/a, 
data categories on serum levels, blood cell counts, etc. Data categories that were redundant were 
also eliminated. 
Next, the cBioPortal resource was used to determine pertinent genetic information related 
to PRCC. The first step was to download the copy number alteration (CNA) data from the 
cBioPortal website. A total of 10,837 genes exhibited a copy number variation. Genes that were 
not considered to be driver genes according to the GISTIC algorithm were eliminated from the 
dataset. This elimination left a total of 426 driver genes with CNA. The driver genes were then 
put into the BCG query to determine how many cases included one or more of the driver CNA 
genes. It was found that 193 of the cases or 66% contained one of the driver CNA genes. In order 
to increase the sample population, mutated driver genes (as determined by Mutsig) were added to 
the query bringing the total of genes up to 517. This addition brought the number of cases to 255 
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or 87% of the dataset. 36 cases did not have an association with one of the 517 driver genes and 
were therefore eliminated for continuity of the data. The driver genes were also divided into 
categories based on their cytoband for future reference. 
Subsequently, the remaining 255 cases were reviewed to determine whether or not they 
were designated type 1 or type 2 PRCC.  Out of the 255 cases, 115 cases had an NA designation 
in the type category.  The pathology report of each of the 115 cases was reviewed to see if a 
pathologist had designated the tumor as either type 1 or type 2. At the conclusion of this analysis 
88 cases were type 2, 69 cases were type 1 and 83 cases remained NA. The 83 NA cases were 
subsequently removed from the dataset in order to preserve the validity and continuity of the 
data. Furthermore, seven cases were determined to be a mix of type 1 and type 2 histology and 
were also removed. Additionally, eight more cases were determined to favor a different cancer 
type per the reviewing pathologist. These eight cases did not include a TCGA addendum that 
disputed the cancer typing and therefore were removed from this dataset. (See Figure 1) 
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Fig. 1 Consort diagram describing TCGA-KIRP data extraction. 
Analysis  
Descriptive Statistics and Survival Analysis 
First descriptive statistics were determined using excel for each of the domains; 
demographics, increased risk factors and genetic pathways. Then a survival analysis was 
conducted for the TCGA-KIRP analytic file using R version 3.6.2. A cox-proportional hazard 
model was fitted on the overall survival times of 156 patients (1 had a survival time of 0 
indicating that they were diagnosed post-mortem or there was an error in entry) to determine if 
there were evidence that survival rates differ between Type 1 and 2 PRCC.  
Logic Regression 
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For the next three phases of our investigation statistical analysis for this data was 
performed using SAS program software package for Windows. The demographic model 
selection included age at diagnosis, race, ethnicity and sex, as candidate descriptors relating to 
PRCC tumor type. The demographic model selection utilized forward selection with a relaxed p 
value (<0.1) to determine the appropriate variables to be included in the model. The selected 
demographic model included Age at Diagnosis (OR 1.045 95% CI 1.014, 1.078 Table 5)  as well 
as 3 Category Race (which was not significant at the .1 level when included in the final candidate 
model but had a sufficient p-value to be selected for inclusion) was used as the baseline model 
for the increased risk factor variables. Each increased risk factor variable, BMI, smoking status, 
prior neoplasms and prior malignancies, were added univariately to the demographic model 
controlling for age at diagnosis and race to identify associations. 
Results 
Descriptive Statistics 
Of the 69 type 1 tumors, 50 were male and 19 were female with a median age of 60 
(range 28 to 82).  In terms of race 46 were white, 18 were black or African American, 5 were 
unspecified and for ethnicity 62 were non-Hispanic or Latino, 2 were Hispanic or Latino and 5 
were unspecified. Of the 88 type 2, 61 were male and 27 were female with a median age of 65 
(range 28 to 88). In terms of race 66 were white, 15 were black or African American, 7 were 
unspecified and for ethnicity 75 were non-Hispanic or Latino, 5 were Hispanic or Latino and 8 
were unspecified (Table 1). Due to the sparsity in the demographic factor levels the following 
variable levels were collapsed; Asian and American Indian. Smoking categories were defined as 
life-long non-smoker (1), current smoker (2), reformed smoker >15years (3), reformed smoker 
<15 years (4) and reformed smoker unknown length (5). For type 1 tumors 30 were category 1, 
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10 were category 2, 10 were category 3, 7 were either category 4 or 5 smokers and 11 were 
unspecified. For type 2 PRCC tumors 36 were category 1, 11 were category 2, 14 were category 
3, 20 were category 4 or 5 and 7 were unspecified.  Once again due to sparsity in the increased 
risk factor levels the following variables were collapsed; smoking category 4 and 5. Prior 
neoplasms were defined as either yes or no with 2 yes in type 1 and 9 in type 2.  Similarly, prior 
malignancies were also defined as either yes or no with 16 yes in type 1 and 14 in type 2 (Figure 
2).  Lastly the most common pathway in type 1 was the MAPK pathway and in type 2 was the 
PI3K pathway Figure 3).  
Overall Survival 
The hazard ratio (comparing Type 2 to 1, with Type one being the reference group) was 
2.459 (with 95% CI 0.9723, 6.217) which does not provide sufficient evidence at the 𝛼 =
.05 level that the two types differ significantly in all-cause survival. However, given the 
relatively small sample size and high rate of censoring (70.3% for Type 1 and 52% for Type 2, 
which consequently prevents us from being able to report median survival without making 
parametric assumptions) it is not surprising that our results do not provide as striking a contrast 
between the two as was found in Wong et al. (2019). Survival rates are illustrated via the Kaplan 
Meier curve included in Figure 2. 
Logistic Regression 
Odd ratios (OR) and confidence intervals (CI) are reported in Tables 5 and 6 for each 
variable in the increased risk factor and pathway analyses. Out of the increased risk factor 
variables investigated we found that smoking appeared to be associated with increased risk of 
Type 2. Specifically, being a reformed smoker of unknown length or less than 15 years (these 
two categories were grouped together due to sparsity) was positively associated with Type 2 
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PRCC compared to life-long non-smokers (OR 3.241 95% CI 1.066, 9.853 Table 5). None of the 
other increased risk factors had a significant association with tumor type. In the pathways 
analysis we observed one significant association and that was a significant difference between 
MAPK and PI3K with PI3K being significantly associated with Type 2 (OR 4.968 95% CI 
1.759, 14.031 Table 6).   In all analyses Type 1 was used as the reference level for each model 
and the OR correspond to odds of Type 2 vs 1. 
Discussion 
To the best of our knowledge our study is the first to collectively examine the 
demographic, increased risk and pathway associations between type 1 and type 2 PRCC tumors.  
Furthermore, while our findings with respect to the survival analysis were not significant at the 
𝛼 = .05 level (in our setting p=.0573), it does provide marginal evidence to confirm the findings 
of Wong et al. (2019) in that survival rates for Type 2 are on average shorter than those for Type 
1. Our secondary data analysis was limited to a small population sample with a lot of
missingness among the dataset. None the less, our study certain variables were found to have an 
increased probability of being associated with type 2 PRCC tumors. The first variable found to 
be significant was age at diagnosis with an increase in age at diagnosis being indicative of an 
increased risk of type 2. This finding is supported by the fact that 20% of type 1 tumors have an 
association with a germline MET mutation and literature has shown that having a germline 
mutation is positively associated with a younger diagnosis age (Lineman et al. 2015). Although 
there are germline mutations associated with type 2 PRCC tumors, they are less prominent than 
type 1 (Lineman et al. 2015; Hsieh et al. 2018).  
Smoking was the only increased risk factor that was significant in determining the 
probability of having the type 2 tumor type. Individuals who were reformed smokers of less than 
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15 years (as well as reformed smokers of unknown length) had a greater risk of developing a 
type 2 tumor as compared to lifelong non-smokers. Furthermore, type 2 PRCC tumors tend to be 
sporadic as compared to type 1, meaning that increased risk factors may have a greater impact on 
the development of type 2 tumors (Yin et al. 2015). However, further research needs to be 
conducted on the effects of smoking on the growth of specific tumor subtypes. Additionally, the 
increased risk factor dataset had a large amount of missingness with prior neoplasm having the 
most missingness (n=90). Further research should be conducted on a larger sample size with less 
missingness to compare increased risk factors variables between tumor types, specifically prior 
neoplasms. Neoplasms have been associated with a number of renal cell cancer syndromes that 
are considered to increase the risk of PRCC. The most common renal cell cancer syndrome, von 
Hippel-Lindau syndrome, is characterized by benign tumor growths and has a 40% chance of 
developing renal cancer, including type 2 PRCC. Additionally, hereditary leiomyomatosis and 
renal cell cancer (HLRCC), is characterized by harmatomas and also an increased risk of 
developing type 2 PRCC (Paquin & Fasolino 2020; Modi & Singer 2016). Considering the 
number of renal cell cancer syndromes that are both associated with an increased PRCC risk and 
are characterized by neoplasms; further research should be conducted to determine if prior 
neoplasms is a determining factor in PRCC subtype.  
The findings in this study have potential implications for future treatment avenues. The 
higher rate of MAPK pathway in type 1 supports the ongoing studies of the use of MET in 
clinical trials.  MET codes for c-Met, a tyrosine kinase protein that is involved with the MAPK 
pathway. When c-Met binds to its ligand, HGF, a downstream cascade is started that leads to the 
activation of the MAPK pathway which promotes cell migration and tumor proliferation (Zhang 
et al. 2018). Seeing as 20% of type 1 tumors contain a MET mutation, it is not surprising that 
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MAPK is the preferred pathway of type 1 tumors. Furthermore, the PI3K pathway was found to 
be significant in the probability of having a type 2 tumor as well as being the preferred pathway 
of type 2.  The findings in this study support the ongoing efforts in determine drug treatment 
therapies that target the PI3K pathway. PI3K is comprised of lipid kinases that once activated, 
begin a downstream cascade that leads to cell growth and survival. PI3K pathway has a strong 
association with the inactivation of PTEN, which has been correlated poor patient outcomes 
(Yang et al. 2019; Bazzichetto et al. 2019).  
Conclusion 
Despite the imperfect database this study found that there is a trend in the data that is 
clinically significant. Furthermore, this study provides the framework for future more 
comprehensive research on the demographic, increased risk factor and genetic pathway 
differences between PRCC type 1 and type 2 tumors. Future investigations should include a 
more complete dataset with additional potential risk factors. Given the differences in survival 
rates, such investigations will provide clinicians a better understanding of tumor types allowing 
for quicker more accurate diagnosis and evidence based treatment plans.  
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Fig. 4.2 Descriptive Statistics for Demographic Factors 
Type 1 Type 2 
Gender (n=158) 
Male 50 61 
Female 19 27 
Race (n=149) 
White 46 66 
Black or African American 18 15 
Other 0 4 
Mean Age (n= 156) 60 (Range 28 to 82) 64.5 (Range 28-88) 
Ethnicity (n= 144) 
Hispanic or Latino 2 5 
Not Hispanic or Latino 62 75 
Fig. 4.3 Descriptive Statistics for Increased Risk Factors 
Type 1 Type 2 
Smoking History Category 
(n=146) 
 1 30 36 
2 10 11 
3 10 14 
4/5 7 20 
Prior Neoplasm (n= 95) 
Yes 2 9 
No 36 48 
Prior Malignancy (n= 156) 
Yes 16 14 
No 55 77 
Mean BMI (n=123) 35.88 27.72 
Fig. 4.4 Descriptive Statistics for Pathways 
Type 1 Type 2 
Pathway (n=157) 
MAPK 31 23 
HIPPO 2 3 
PI3K 8 27 
P53 13 16 
WNT 7 6 
NOTCH 5 9 
TGF 2 3 
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TNF 1 1 
 
Table 4.1. Demographics Model 
 
OR 95% CI for OR 
Age at Diagnosis  1.045 1.014 1.078 
White Reference  - - 
Black or African American 0.677 0.301 1.525 
Other 5.601 0.54 58.089 
Odds ratios (ORs) associated with the selected demographic model. The model was selected using 
forward selection (criteria for entry p<.1) from a candidate model including age at diagnosis, race, sex, 
and ethnicity. The final model had an effective sample size of 150. 
 
Table 4.2.  Increased Risk Factor Model   
Variable Level OR 95% CI for OR 
BMI      
(n=121)   0.989 0.963 1.015 
Smoking  
(n=131)  
Smoke 1 Reference - - 
Smoke 2 1.141 0.381 3.415 
Smoke 3 0.916 0.322 2.611 
Smoke 4or 5 3.241 1.066 9.853 
Malignancy   
(n=150) 
No Reference - - 
Yes 0.614 0.265 1.421 
Neoplasm  
(n=91*)     
No Reference - - 
Yes 3.736 0.698 19.999 
 
Odds ratios and associated confidence intervals for increased risk factor variables. Each variable, BMI, 
smoking, malignancy and neoplasm were added to the demographic model (i.e. the model containing Age 
at Diagnosis and Race) one at a time and the odds ratios for each variable and level are reported here, 
controlling for age at diagnosis and race. Effective sample sizes are included under the variable labels. 
Table 4.3. Pathway Model  
Pathway OR 95% CI for OR 
MAPK Reference  - - 
HIPPO 7.43 0.58 95.242 
NOTCH 3.076 0.768 12.32 
P53 1.783 0.678 4.69 
PI3K 4.968 1.759 14.031 
TGF 2.264 0.313 16.35 
TNF 0.767 0.041 14.309 




Odds ratios and associated confidence intervals for individual pathways. Note that the CI for PI3K does 
not contain 1 which indicates that PI3K is (significant and) positively associated with Type 2. ORs were 












Synthesis of Manuscripts 
Papillary renal cell carcinoma (PRCC) is the second most common renal cell carcinoma 
(RCC), following clear cell, comprising of 15-20% of all RCCs. PRCC is a heterogenous disease 
that consists of two histologically distinct subtypes; type 1 and type 2. PRCC is often 
asymptomatic and difficult to detect with as many as 20-50% of tumors being discovered 
incidentally (Marsaud et al 2015; Prochazkova et al. 2018). Furthermore, the treatment options 
remain limited for PRCC tumors with nephrectomy continuing to be the preferred treatment. 
Until recently research has been focused on the more common RCC subtype, clear cell. 
Additionally, PRCC studies have been broadly based with little research being done on 
comparing PRCC tumor subtypes.  PRCC subtypes are genetically diverse and present with 
varying patient outcomes (Fernandes & Lopes 2015; Pal et al. 2019). Considering that healthcare 
providers are at the forefront of the diagnosis and treatment of PRCC, it is imperative that they 
be able to distinguish between PRCC subtypes.  
All the chapters in this dissertation work together to create a cohesive and comprehensive 
understanding of PRCC as a whole, as well as understanding PRCC subtypes 1 and 2. The 
purpose of this body of work was first to discuss the status of the current literature on PRCC 
including subtypes, genetic underpinnings, epidemiology and treatment options. The second 
purpose was to define what is known on differentiating between PRCC subtypes and to perform 
a secondary data analysis to determine if there were clinically relevant differences between 
PRCC type 1 and type 2 tumors.  
In order to better understand PRCC as a disease, the first manuscript (chapter 2) 
performed a comprehensive review and synthesis of the literature discussing the subtype 
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classification, genetic pathways and epidemiology of the disease as it relates to clinicians. This 
review found that PRCC is a genetically diverse disease with multiple subtypes. Currently, there 
are two main histologically diverse subtypes; type 1 and type 2. Type 1 tumors are characterized 
by a single layer of basophilic cells with sparse cytoplasm and small oval nuclei. Type 1 tumors 
can be sporadic or hereditary and 20% of type 1 tumors present with a mesenchymal epithelial 
transition (MET) gene variation (Marsuad et al. 2016). Conversely, type 2 tumors present with a 
pseudostratified layer of cells with eosinophilic cytoplasm and large nuclei. Type 2 tumors can 
also be sporadic or hereditary and have been associated with fumarate hydratase (FH) as well as 
vascular endothelial growth factor (VEGF) gene variations (Modi and Singer 2015: TCGA, 
2016: Marsuad et al. 2015).  This literature review found that there is a lack of knowledge 
concerning the epidemiology of type 1 and type 2 PRCC tumors. Furthermore, this review found 
that PRCC tumors are treated the same as clear cell tumors with nephrectomy being the preferred 
treatment method (Fernandes & Lopes 2015; Dengina et al. 2017). This manuscript differs from 
the others in that it is a description of PRCC as whole and provides the necessary background for 
manuscripts two and three.  
After careful review of the literature, the second manuscript (chapter 3) aimed to further 
examine the genetic underpinnings of PRCC tumors. The purpose of this literature synthesis was 
to describe the various renal cell cancer syndromes that are associated with RCC.  The most 
common renal cancer syndrome is von Hippel-Lindau Syndrome which is characterized by 
mutations in the VHL gene. Individual’s with von Hippel-Lindau Syndrome have a 40% chance 
of developing an RCC, including the PRCC subtype (Gupta et al. 2017).  Similarly, Hereditary 
Leiomyomatosis and Renal Cell Cancer is characterized by mutations in the FH gene and has 
been associated with the development of type 2 PRCC tumors (Arenas Valencia et al., 2017). 
72 
 
Considering that numerous renal cancer syndromes present with benign neoplasms, this literature 
review provided the basis for using prior neoplasms as a variable for the secondary data analysis 
(Paquin & Fasolino 2020). The second manuscript differs from the first manuscript in that it 
focuses specifically on hereditary causes of PRCC. Furthermore, this manuscript is a narrow-
based literature review unlike manuscript 3, which is original research.  
The third manuscript (chapter 4) in this dissertation performed a secondary data analysis 
using The Cancer Genome Atlas- Kidney Renal Papillary Cell Carcinoma (TCGA-KIRP) data to 
determine if there were significant differences between type 1 and type 2 PRCC tumors that can 
be utilized by clinicians. The secondary data analysis focused on epidemiological factors, age, 
ethnicity, gender, race; increased risk factors, body mass index (BMI), smoking history, 
neoplasm history, and malignancy history; and tumor subtype pathway preference.  This analysis 
found that older age at diagnosis was significant in the probability of having a type 2 PRCC 
tumor. Similarly, this study also found that being African American had a negative probability of 
having a type 2 tumor. In terms of pathway preference, type 2 tumors were found to significantly 
prefer the PI3K pathway and type 1 tumors utilized the MAPK pathway. Lastly, this study found 
that there is a significant difference in overall survival rates between tumor types with type 2 
tumors having a lower overall survival rate. Manuscript three is an original study that is based on 
the literature reviews performed in manuscripts one and two.  
Contribution to the Knowledge of PRCC and Healthcare Genetics 
Up until recently research has been based on the clear cell subtype of RCC and what 
research that has been done specifically on PRCC, has focused on the cellular molecular 
components of the disease. Furthermore, there is a gap in the knowledge concerning the 
clinically significant differences between type 1 and type 2 PRCC tumors (MacLennan & Cheng 
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2020: Lineman et al 2015). This dissertation contributed to the current knowledge of PRCC by 
determining that there are certain significant differences, age at diagnosis, race, genetic pathway 
preference, and overall survival, between type 1 and type 2 PRCC tumors. The findings in this 
dissertation are relevant to healthcare genetics because they provide the foundation for evidence-
based practice concerning the diagnosis, prognosis and treatment of PRCC tumors. Furthermore, 
this dissertation provides the background needed for future research initiatives that focus on 
further defining the differences between type 1 and type 2 PRCC tumors.  
Knowledge Gaps and Future Directions 
Although this dissertation presented a comprehensive overview of PRCC and the 
subtypes associated with the disease, there are still gaps in the knowledge. The first gap is that 
although type 1 and type 2 PRCC tumors are the most recognized, there are more than two 
subtypes associated with PRCC.  Additionally, tumors can be heterogenous and present with 
features of both type 1 and type 2 subtypes (Marsaud et al 2015; Prochazkova et al. 2018). This 
dissertation was limited to the data currently available and therefore restricted to type 1 and type 
2 PRCC tumors, not accounting for additional subtypes. Another limitation was that this 
dissertation did not cover all known renal cancer syndromes. There are other syndromes, 
specifically hereditary papillary renal cell carcinoma (HPRCC) which is characterized by MET 
variations, that predispose individual’s to PRCC. Although quite rare, HPRCC is associated with 
an almost 100% chance of developing type 1 PRCC tumors (Maher 2018). This dissertation 
focused on the most common renal cancer syndromes and is not a comprehensive list. Lastly, 
this dissertation was limited to a small sample population of already collected data, thus the 
research questions were limited to those that could be answered by the available data. 
Additionally, the sample size was further limited with each variable tested in the final 
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manuscript. This means that a larger sample size could provide additional insights into variables 
that can distinguish between type 1 and type 2 PRCC tumors.  
The findings in this study indicate the need for further research to better distinguish 
between type 1 and type 2 PRCC subtypes. First there has to be research to clearly designate 
what constitutes PRCC subtypes. Type 1 and type 2 subtypes have consistently been recognized 
as the primary PRCC subtypes. However, these two subtypes have been characterized by their 
histology and a recent study has proposed other options for tumor typing (Mager et al. 2019). 
Having a clear system to properly subtype PRCC tumors is needed to insure the validity of future 
PRCC research. 
Second, there is a need for a new descriptive and comprehensive PRCC dataset. 
Currently, the TCGA-KIRP remains the only source for a large collection of PRCC data that 
includes clinical, genetic and risk factor information. However, this dataset is largely incomplete 
and the last sample was collected in 2013 (Lineman et al, 2016). There is a need for new research 
that is more current and is comprised of more complete increased risk factor data, including 
chemical exposure, prior neoplasms, renal cancer syndrome status, and smoking history. 
Furthermore, this study must also include the specific subtype of each PRCC tumor as defined by 
the current literature.  
Thirdly, additional research on PRCC preferred genetic pathways should be conducted to 
better understand what role pathways play in determining PRCC subtypes. Pathway preference is 
important in the development of tumor specific treatment options. Given the heterogenous nature 
of both types of PRCC, understanding the preferred genetic pathways of each subtype will lead 
to better evidence-based treatment options. Current clinical trials are focused on specific genes 
(namely MET) or individuals with certain renal cancer syndromes (Clinicaltrials.gov, 2020). 
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Focusing treatment research on genetic pathways as opposed to specific genes, will lead to the 
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List of Acronyms 
Cancers 
ccRCC – Clear Cell Renal Cell Carcinoma 
ccPRCC= Clear Cell Papillary Renal Cell Carcinoma 
PRCC – Papillary Renal Cell Carcinoma 
RCC – Renal Cell Carcinoma 
Genes/Proteins 
BAP1 - BRCA1 Associated Protein-1  
BRCA1 = Breast Cancer type 1 Susceptibility Protein 
EGFR = Epidermal Growth Factor Receptor 
FH- Fumarate Hydratase 
FLCN – Folliculin  
FRA7G = Aphidicolin-Inducible Fragile Site  
HER2 = human epidermal growth factor receptor 2 
HGF = Hepatocyte growth factor  
HIC-1 = Hypermethylated in Cancer 1 
KLLN = Killin 
MET – Mesenchymal Epithelial Transition 
MITF = Melanocyte Inducing Transcription Factor 
P53 = Tumor Protein 53 
PTEN = Phosphatase and Tensin Homolog  
RTK = Tyrosine Kinase Receptor  
SDH = Succinate Dehydrogenase Complex Iron Sulfur  
SDHB = Succinate Dehydrogenase Complex Iron Sulfur Subunit B 
SDHD = Succinate Dehydrogenase Complex Iron Sulfur Subunit D 
TAU= microtubule-associated protein tau 
TOP2A= topoisomerase 2-alpha 
TSC1- TSC Complex Subunit 1  
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VEGF = Vascular Endothelial Growth Factor  
VHL - Von Hippel–Lindau tumor suppressor  
Pathways 
MAPK = Mitogen Activated Protein Kinase  
P53 = Tumor Protein 53 pathway 
PI3K = Phosphoinositide 3-kinases 
TGF = Transforming growth factor beta 
TNF = Tumor Necrosis Factor 
WNT = blending of Wingless and Int-1 
Syndromes/Diseases 
BHD = Birt-Hogg-Dubé Syndrome  
CS = Cowden Syndrome 
ESRD = End Stage Renal Disease  
HRLCC= Hereditary Leiomyomatosis and Renal Cell Cancer  
HNPCC = Lynch Syndrome/ Hereditary Non-Polyposis Colorectal Cancer  
HPRCC = Hereditary Papillary Renal Cell Carcinoma  
TSC = Tuberous Sclerosis Complex  
VHL = von Hippel-Lindau Disease 
Databases 
BCR= Biospecimen Core Resource  
cBioPortal = cBioPortal for cancer genomics 
TCGA-KIRP- The Cancer Genome Atlas- Kidney Renal Papillary Cell Carcinoma 
Terms 
BMI – Body Mass Index 
CNA = Copy Number Alteration 
CI = Confidence Interval 
OR = Odds Ratio 
 
